Page 215 of 400: studies 2,141 to 2,150 of 3,999, newest first. Back to the serotonin overview
August 8, 2025 Gary Laderman
Chapter 7 examines the rich and surprising history of psychedelics and religious life in the Americas, and in modern American life. The sacred drugs du jour now and likely into the future are psychedelics. LSD, psilocybin, MDMA, DMT, ayahuasca, and mescaline are several of the organic and synthetic psychoactive, serotonergic agents that have entered popular consciousness and are in the process...
August 8, 2025 Sebastián Malleza
After completing this activity, participants should be able to: Identify the unique pharmacological mechanism of dextromethorphan/bupropion as an oral NMDA receptor antagonist combination and describe how bupropion's CYP2D6 inhibition enhances dextromethorphan's bioavailability to produce rapid antidepressant effects within the first week of treatment. Recognize absolute contraindications for...
Frontiers in Psychiatry August 6, 2025 Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell et al. 3 citations
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological...
The Brown University Psychopharmacology Update August 4, 2025
Use of selective serotonin reuptake inhibitor (SSRI) antidepressants has been associated with reduced intensity of emotional experience. Conversely, some research has shown that use of psilocybin in patients with depression leads to an increase in responsiveness to emotional face stimuli, suggesting that the psychedelic generates a transient elevation in mood. Investigators conducted a...
Frontiers in Psychiatry August 4, 2025 Wierzbicka Małgorzata, Renata Kopczyk, Alexander L. Gerlach et al. 1 citation
Depression prevalence is markedly elevated in oncological patients, particularly among head and neck cancer (HNC) cohorts, who face twice the prevalence of major depressive disorder (MDD) compared to other cancer populations. MDD in this context independently predicts poorer clinical outcomes and increased morbidity. HNC management often involves acute surgical interventions with disfiguring...
The International Journal of Neuropsychopharmacology August 1, 2025 Argel Aguilar-Valles, Dhiral Kot, Vern Lewis et al.
Abstract Background Major depressive disorder (MDD) is a multifactorial and heterogeneous disorder that affects around 280 million individuals worldwide, with approximately 80 million experiencing treatment-resistant depression (TRD). Neuronal hypotrophy and axon hypomyelination in the prefrontal cortex (PFC) are hallmark features of MDD, highlighting the need for treatments that address these...
The International Journal of Neuropsychopharmacology August 1, 2025 Bernard Lerer, Peretz Golding, Michal Brownstien et al.
Abstract Background We have designed a novel psychedelic-derived compound (HBL20017) characterized by high functional efficacy at 5-HT2A, 5-HT1A, and 5-HT2C receptors. We assessed its hallucinogenic properties and its potential for OCD treatment on the marble burying test (MBT) and in mice homozygous for deletion of the Synapse Associated Protein 3 (SAPAP3) gene. These mice manifest severe,...
The International Journal of Neuropsychopharmacology August 1, 2025 Jonathan W. Kanen, Andrea I. Luppi, Q. Luo et al.
Abstract Background The REBUS (RElaxed Beliefs Under pSychedelics) and the anarchic brain model of psychedelic drug action proposes that confidence in beliefs – and thus expectations (priors) – are relaxed under these drugs. The brain makes inferences to minimize surprise, or discrepant expectations and outcomes (prediction error [PE]), and better model the world. We recently showed that the...
Psychoactives August 1, 2025 L. Cazorla, Sylvie Alaux, Caroline Amberger et al.
Despite growing evidence supporting the efficacy of LSD-assisted psychotherapy in treating major depressive disorder (MDD), identifying reliable psychopharmacological biomarkers remains necessary. Oxytocin, a neuropeptide implicated in social bonding and flexibility, is a promising candidate due to its release following serotonergic psychedelic administration in healthy individuals; however,...
Cureus August 1, 2025 Brett Hughes, Soz Mirza, Manasi Ponamala et al.
The stresses of the Coronavirus Disease of 2019 (COVID-19) pandemic highlighted the burden of psychiatric disorders within the pediatric population, revealing a pre-existing need for rapid-onset therapies that have since driven efforts to expand effective therapeutic interventions. In this narrative review, we utilized the Preferred Reporting Items for Systematic reviews and Meta-Analysis...